Cargando…

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Small, Jeffrey, Washburn, Erik, Millington, Karmaine, Zhu, Junjia, Holder, Sheldon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707010/ https://www.ncbi.nlm.nih.gov/pubmed/29221116 http://dx.doi.org/10.18632/oncotarget.19618

Ejemplares similares

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways
por: Xie, Yingwei, et al.
Publicado: (2021)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
por: Lee, Alex Q., et al.
Publicado: (2021)

Diagnosis and imaging characteristics of a juvenile fibroadenoma in a 2–year-old patient: a case report
por: Woodard, Stefanie, et al.
Publicado: (2017)

Abemaciclib for breast cancer
Publicado: (2020)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Spontaneous regression of adrenal metastasis from renal cell carcinoma after sunitinib withdrawal: case report and literature review
por: Yang, Ti-Yuan, et al.
Publicado: (2018)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles()
por: Gaustad, Jon-Vidar, et al.
Publicado: (2017)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
por: Gruenwald, Viktor, et al.
Publicado: (2010)

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma
por: Verhoest, Grégory, et al.
Publicado: (2014)

Mimics of Duplication Cysts: Intraperitoneal Nodules in a 14-Year-Old Boy
por: Ohanessian, Sara E, et al.
Publicado: (2015)

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate
por: Chappell, Jill C., et al.
Publicado: (2018)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
por: Nagaya, Naoya, et al.
Publicado: (2018)

A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib
por: Lauro, Salvatore, et al.
Publicado: (2014)

DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts()()
por: Wegner, Catherine S., et al.
Publicado: (2018)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma
por: Liman, Andrew D., et al.
Publicado: (2018)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
por: Shikuma, Hiroyuki, et al.
Publicado: (2019)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
por: Wu, Zeshen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_67n8spahae638gc3e33fhibt2d